Clinical Trials Study
Copyright ©The Author(s) 2025.
World J Gastroenterol. Jul 7, 2025; 31(25): 105518
Published online Jul 7, 2025. doi: 10.3748/wjg.v31.i25.105518
Table 1 Demographic, clinical, histological and biochemical characteristics of the enrolled patients
Characteristic
Entire cohort (n = 120)
No MASH (n = 39)
MASH (n = 81)
P value
Sex (male)68 (56.7)24 (61.5)44 (54.3)NS
Age (years)49 ± 1150 ± 1049 ± 11NS
BMI (kg/m2)33.2 ± 7.131.7 ± 6.934.0 ± 7.1NS
Obesity72 (60.0)19 (48.7)53 (65.4)0.08
Diabetes35 (29.1)7 (17.9)28 (34.5)0.06
Hypertension54 (45.0)14 (35.9)40 (49.4)NS
Biochemical profile
Platelet count (× 106/mL)230.9 ± 68.2230.6 ± 59.0231.0 ± 72.6NS
AST (IU/L)43.7 ± 38.932.3 ± 14.349.3 ± 45.30.02
ALT (IU/L)59.2 ± 50.242.4 ± 23.967.2 ± 57.20.01
GGT (IU/L)65.7 ± 56.268.6 ± 73.264.3 ± 47.3NS
ALP (IU/L)74.7 ± 37.185.7 ± 52.669.6 ± 25.90.03
Albumin (g/L)40.9 ± 3.541.6 ± 3.240.5 ± 3.5NS
Triglycerides (mg/dL)157.9 ± 90.6137.5 ± 53.7168.0 ± 103.1NS
Total cholesterol (mg/dL)196.3 ± 44.2195.9 ± 42.0196.5 ± 45.5NS
HDL (mg/dL)44.7 ± 14.350.1 ± 22.542.7 ± 8.80.04
FIB41.54 ± 2.671.20 ± 0.611.71 ± 3.22NS
NFS-1.24 ± 1.71-1.54 ± 1.48-1.10 ± 1.80NS
Agile3 +0.14 (0.06-0.53)0.11 (0.05-0.33)0.23 (0.06-0.60)0.02
Histological findings
Steatosis grade< 0.01
147 (39.2)39 (100)8 (9.9)
249 (40.8)0 (0)49 (60.5)
324 (20.0)0 (0)24 (29.6)
Lobular inflammation grade< 0.01
04 (3.3)4 (10.2)0 (0)
190 (75.0)35 (89.8)55 (67.9)
224 (20.0)0 (0)24 (29.6)
32 (1.7)0 (0)2 (2.5)
Hepatocyte ballooning grade< 0.01
013 (10.8)13 (33.3)0 (0)
194 (78.4)26 (66.6)68 (84.2)
213 (10.8)0 (0)13 (15.8)
Fibrosis stage0.01
03 (2.5)3 (7.7)0 (0)
143 (35.8)19 (48.8)24 (29.6)
240 (33.3)12 (30.7)28 (34.6)
330 (25.0)4 (10.2)26 (32.1)
44 (3.4)1 (2.6)3 (3.7)
Elastographic measurements
LS by TE (kPa)7.9 ± 5.06.2 ± 3.28.7 ± 5.30.01
2D-SWE (kPa)7.34 ± 3.166.61 ± 3.027.70 ± 3.190.07
CAP (dB/m)302.9 ± 67.2250.5 ± 74.5328.2 ± 45.9< 0.01
Att.PLUS (dB/cm/mHz)0.52 ± 0.110.55 ± 0.120.51 ± 0.100.06
SSp.PLUS (m/s)1530 (1505-1550)1545 (1525-1570)1525 (1500-1545)< 0.01
Vi.PLUS (Pa.s)2.24 ± 0.512.04 ± 0.542.34 ± 0.480.03
Table 2 Performance of ultrasound non-invasive diagnostic tests and VAS-MASH-US score for predicting moderate-to-severe steatosis (S ≥ 2), presence of both lobular inflammation and ballooning (inflammation ≥ 1 and ballooning ≥ 1), MASH (NAS score ≥ 4 and least 1 point at steatosis, lobular inflammation, and ballooning) and Fibrosis
Variable
Cutoff value
AUC (95%CI)
Sensitivity (%)
Specificity (%)
PPV (%)
NPV (%)
P value
Steatosis ≥ 2
CAP (dB/m)2750.83 (0.75-0.91)94.566.081.288.6Reference
CAP (dB/m)301178.074.582.668.6
Att.PLUS (dB/cm/mHz)0.440.60 (0.50-0.70)89.431.545.682.1< 0.01
SSp.PLUS (m/s)15350.71 (0.61-0.81)70.265.756.977.40.02
Inflammation ≥ 1 and ballooning ≥ 1
Vi.PLUS (Pa.s)2.30.72 (0.59-0.86)52.892.898.220.6Reference
MASH
Vi.PLUS (Pa.s)2.10.68 (0.58-0.79)69.164.180.050.0Reference
VAS-MASH-US score0.600.75 (0.65-0.84)79.066.783.160.40.14
0.4890.043.676.665.4
0.8430.990.086.238.4
Fibrosis ≥ 2
TE (kPa)6.40.75 (0.65-0.83)72.971.780.662.3Reference
2D-SWE (kPa)6.40.69 (0.60-0.79)59.573.978.653.10.25
FIB-41.070.65 (0.55-0.75)62.258.770.849.10.10
NFS-0.970.69 (0.59-0.79)55.478.380.452.20.40
Vi.PLUS (Pa.s)2.30.64 (0.53-0.74)59.571.777.252.40.04
Fibrosis ≥ 3
TE (kPa)8191.283.768.996.0Reference
8.40.93 (0.87-0.99)85.391.980.594.0
12135.397.784.678.5
2D-SWE (kPa)7.20.90 (0.85-0.95)88.281.461.793.10.43
FIB-41.260.80 (0.71-0.89)70.674.452.286.50.01
NFS-1.120.83 (0.75-0.90)88.273.256.694.00.03
Agile3 +0.420.93 (0.88-0.98)85.389.576.393.90.99
Vi.PLUS (Pa.s)2.10.81 (0.74-0.89)10058.148.6100< 0.01
Table 3 Univariate and multivariate analysis evaluating variables associated with metabolic dysfunction-associated steatohepatitis
VariableUnivariate analysis
Multivariate analysis
OR (95%CI)
P value
OR (95%CI)
P value
Sex (male)0.74 (0.34-1.62)0.45
Age0.98 (0.95-1.02)0.48
Att.PLUS0.03 (0.01-1.06)0.06
SSp.PLUS0.98 (0.97-0.99)< 0.010.98 (0.97-0.99)< 0.01
CAP1.02 (1.01-1.03)< 0.01
Vi.PLUS3.59 (1.47-8.78)< 0.013.12 (1.20-8.16)0.02
BMI (kg/m2)1.05 (0.99-1.11)0.11
Triglycerides1.00 (0.99-1.01)0.11
Total cholesterol1.00 (0.99-1.01)0.94
Diabetes2.42 (0.95-6.17)0.06
Hypertension1.74 (0.79-3.82)0.16
ALT1.02 (1.01-1.03)0.011.03 (1.01-1.06)0.05
AST1.03 (1.01-1.06)0.02

  • Citation: Liguori A, Ainora ME, Di Gialleonardo L, Viceconti N, Petrucci L, Esposto G, Giustiniani MC, Mignini I, Borriello R, Galasso L, Paratore M, Garcovich M, Riccardi L, Pompili M, Grieco A, Gasbarrini A, Miele L, Zocco MA. Multiparametric ultrasound for non-invasive assessment of liver steatosis, fibrosis, and inflammation in metabolic dysfunction-associated steatotic liver disease. World J Gastroenterol 2025; 31(25): 105518
  • URL: https://www.wjgnet.com/1007-9327/full/v31/i25/105518.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v31.i25.105518